Key facts
- Curtana Pharmaceuticals’s last known valuation is $19.9M (Jan 2023).
- It has raised $10.1M.
- Notable investors include University of California, ACC Bioscience Incubator, AngelMD, Biosense Global, Cancer Prevention and Research Institute of Texas — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Curtana Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Curtana Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Curtana Pharmaceuticals
Developer of targeted therapies designed to treat brain cancer. The company focuses on adding an Olig2 inhibitor to conventional options at diagnosis to treat glioblastoma in adults and pediatric medulloblastoma in children, enabling physicians to treat their patients in an enhanced manner.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2013
- Employees
- 9
- Website
- curtanapharma.com/
- Ownership
- Privately Held (backing)
Curtana Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Curtana Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Curtana Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.